Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 2.975
-0.215 (-6.74%)
Apr 1, 2025, 3:47 PM CET
Oryzon Genomics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 7.36 | 14.19 | 15.7 | 10.62 | 9.52 | Upgrade
|
| Revenue Growth (YoY) | -48.15% | -9.60% | 47.88% | 11.49% | -7.36% | Upgrade
|
| Cost of Revenue | 0.3 | 0.24 | 0.46 | 0.75 | 0.53 | Upgrade
|
| Gross Profit | 7.06 | 13.95 | 15.23 | 9.87 | 8.99 | Upgrade
|
| Selling, General & Admin | 3.45 | 3.61 | 3.57 | 3.67 | 3.69 | Upgrade
|
| Other Operating Expenses | 8.04 | 14.75 | 17 | 13.07 | 9.45 | Upgrade
|
| Operating Expenses | 11.64 | 18.51 | 20.73 | 16.88 | 13.29 | Upgrade
|
| Operating Income | -4.58 | -4.56 | -5.5 | -7.01 | -4.29 | Upgrade
|
| Interest Expense | -1.23 | -1.89 | -1.12 | -0.46 | -0.47 | Upgrade
|
| Interest & Investment Income | - | 0.03 | 0.01 | 0.01 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.09 | 0.1 | 0.24 | 0.28 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.25 | 0.21 | -0.2 | 0 | - | Upgrade
|
| EBT Excluding Unusual Items | -5.65 | -6.12 | -6.56 | -7.18 | -4.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0 | -0 | Upgrade
|
| Other Unusual Items | 0.08 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Pretax Income | -5.57 | -6.1 | -6.56 | -7.18 | -4.78 | Upgrade
|
| Income Tax Expense | -1.91 | -2.75 | -2.33 | -2.49 | -1.38 | Upgrade
|
| Net Income | -3.67 | -3.35 | -4.23 | -4.69 | -3.4 | Upgrade
|
| Net Income to Common | -3.67 | -3.35 | -4.23 | -4.69 | -3.4 | Upgrade
|
| Shares Outstanding (Basic) | 64 | 61 | 55 | 53 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 64 | 61 | 55 | 53 | 53 | Upgrade
|
| Shares Change (YoY) | 5.73% | 10.10% | 4.80% | - | 15.99% | Upgrade
|
| EPS (Basic) | -0.06 | -0.06 | -0.08 | -0.09 | -0.06 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.06 | -0.08 | -0.09 | -0.06 | Upgrade
|
| Free Cash Flow | -5.69 | -0.57 | -1.92 | -3.8 | -4.97 | Upgrade
|
| Free Cash Flow Per Share | -0.09 | -0.01 | -0.04 | -0.07 | -0.09 | Upgrade
|
| Gross Margin | 95.89% | 98.28% | 97.04% | 92.97% | 94.47% | Upgrade
|
| Operating Margin | -62.26% | -32.16% | -35.02% | -66.07% | -45.06% | Upgrade
|
| Profit Margin | -49.81% | -23.63% | -26.96% | -44.15% | -35.70% | Upgrade
|
| Free Cash Flow Margin | -77.32% | -4.05% | -12.25% | -35.82% | -52.20% | Upgrade
|
| EBITDA | -4.43 | -4.43 | -5.35 | -6.88 | -4.16 | Upgrade
|
| EBITDA Margin | -60.25% | -31.24% | -34.08% | -64.81% | -43.67% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.13 | 0.15 | 0.13 | 0.13 | Upgrade
|
| EBIT | -4.58 | -4.56 | -5.5 | -7.01 | -4.29 | Upgrade
|
| EBIT Margin | -62.26% | -32.16% | -35.02% | -66.07% | -45.06% | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.